Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification Guoliang YaoJianyong YuanJingbo Chen Review 16 November 2023 Pages: 1 - 13
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide Kelsey A. FletcherMai H. AlkurashiAndrew J. Lindsay Research 14 November 2023 Pages: 14 - 23
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study Changkun ZhangXia YouDong Wang Research 17 November 2023 Pages: 24 - 34
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma Jasmine C. HuynhMay ChoEdward J. Kim Research Open access 01 December 2023 Pages: 35 - 43
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I- Daiki TsujiShigeru NakagakiMasaya Watanabe Research 06 December 2023 Pages: 44 - 52
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis Haibo LeiWei SunChunjiang Wang Research 08 December 2023 Pages: 53 - 59
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma Yanfang JiangXintong HuPingwei Zhao Research 10 December 2023 Pages: 60 - 69
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage Yue WangXingyu LinGuan Wang Research 12 December 2023 Pages: 70 - 79
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects Hyun Chul KimEunsol YangKyung-Sang Yu Research Open access 15 December 2023 Pages: 80 - 88
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells Mahtab AfsharzadehJaleh VarshosazFarshid Hasanzadeh Research 21 December 2023 Pages: 89 - 105
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function Jingying YueShuai ShaoMarie M Zhu Research 10 January 2024 Pages: 106 - 115
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis Meng-Ting LiYang HeJi-Sheng Chen Research 23 January 2024 Pages: 116 - 126
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort Oluwadunni E. EmilojuJun YinBrian A. Costello Research 25 January 2024 Pages: 127 - 135
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer Naoyuki NogamiTakaaki TokitoMakoto Nishio Research Open access 01 February 2024 Pages: 136 - 144
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial Andrew J. ArmstrongRavit GevaJudy S. Wang Research Open access 07 February 2024 Pages: 145 - 159